Linde M Morsink

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/195212/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood, 2022, 139, 1694-1706.	0.6	36
2	Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Cancers, 2020, 12, 2339.	1.7	28
3	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. Leukemia, 2020, 34, 1577-1587.	3.3	22
4	Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. Leukemia, 2020, 34, 1701-1705.	3.3	15
5	Novel monoclonal antibody-based therapies for acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2019, 32, 116-126.	0.7	14
6	Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Bone Marrow Transplantation, 2020, 55, 669-672.	1.3	13
7	Pretransplantation MRD in Older Patients With AML After Treatment With Decitabine or Conventional Chemotherapy. Transplantation and Cellular Therapy, 2021, 27, 246-252.	0.6	9
8	Robust COVID-19 vaccination response after allogeneic stem cell transplantation using post transplantation cyclophosphamide conditioning. Blood Cancer Journal, 2022, 12, 6.	2.8	7
9	CombiFlow: Combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones. Blood Advances, 2021, , .	2.5	4
10	Diffuse plane normolipaemic xanthomatosis as a manifestation of monoclonal gammopathy. British Journal of Haematology, 2019, 187, 411-411.	1.2	2
11	Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement. Clinical Oral Investigations, 2022, , 1.	1.4	2